Actinium Pharmaceuticals Announces Engagement of MissionIR Investor Relations Services

ATLANTA, GA -- (Marketwired) -- 01/15/14 -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) (the "Company") today announces that they have engaged the investor relations services of MissionIR. Through a network of investor-oriented sites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital as well as improve shareholder value.

"Actinium is wrapping up a year of tremendous progress in the development of its cancer treatment candidates, and is on the cusp of initiating additional clinical trials," stated Sherri Franklin, Director of Marketing at MissionIR. "MissionIR is pleased to partner with the Company as it starts off a new year of advances with a firm stance and high potential in the biotech industry."

Actinium intends to develop its cancer treatment products through clinical trials and then intends to partner each drug for completion of development and commercialization with an appropriate third party. In working toward this objective, the Company aims to increase brand awareness.

"We're moving closer to the commercialization of our cancer drugs, and want to increase visibility in the investment community and enhance communication with our existing shareholders along the way," Dr. Kaushik J. Dave, President and CEO of Actinium, stated. "Engaging a full-service investor relations firm will help us develop and implement a strategic investor relations campaign to reach this goal. MissionIR is providing a much needed service in the small-cap markets."

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. Through a full suite of investor relations and consultancy services, we help public companies develop and execute a strategic investor awareness plan as we've done for hundreds of others. Whether it's capital raising, increasing awareness among the financial community, or enhancing corporate communications, we offer a variety of solutions to meet the objectives of our clients.

For more information, visit

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information, visit

Forward-Looking Statements

This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information included in this Press Release including such forward-looking statements.


Mission Investor Relations
Sherri Franklin

Source: Actinium Pharmaceuticals, Inc.